Clinical Research Directory

A Phase Ib Clinical Study of AC-003 Capsules in Subjects With aGVHD.

The study was an open-label, single-arm, dose-escalation, Phase Ib, multi-center study to investigate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of AC-003 in patients with grade II-IV SR-aGVHD.

Effects of Resistance Training on Recovery During Hematopoietic Stem Cell Transplantation

This study investigates whether a resistance training program can help patients recovering from hematopoietic stem cell transplantation (HSCT) for hematologic malignancies. HSCT is a vital treatment, but it comes with a high risk of severe complications. These include opportunistic infections caused by low white blood cell counts (neutropenia) and acute graft-versus-host disease (aGVHD), where donor cells attack the patient's body. Additionally, more than half of patients suffered from severe cancer-related fatigue during or after transplantation, which significantly lowers their quality of life. Currently, treatments for these complications rely almost entirely on medication. The purpose of this study is to see if an 8-week elastic band resistance training program can speed up blood cell recovery, reduce the severity of aGVHD, shorten hospital stays, and alleviate cancer-related fatigue. A total of 86 patients preparing for HSCT at Taipei Veterans General Hospital will be randomly assigned to one of two groups: 1. The Resistance Training Group (43 patients): Participants will perform 45-minute elastic band exercises three times a week, starting four weeks before their transplant and continuing until four weeks after. 2. The Control Group (43 patients): Participants will receive standard routine care. The study will compare the two groups by measuring how many days it takes for white blood cells to recover, the occurrence and severity of aGVHD, muscle strength (hand grip and lower limbs), fatigue levels, and the total length of hospital stays.

Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model

To assess the efficacy and safety of using recombinant humanized anti-CD25 monoclonal antibody injection as a prophylactic strategy for reducing the incidence of severe acute graft-versus-host disease (aGVHD) in adult patients at intermediate to high risk, as predicted by the dynamic aGVHD Onset Anticipation Tianjin (daGOAT) model, following allogeneic hematopoietic stem cell transplantation (allo-HSCT).

A Study of iMSC for the Prevention of Acute Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

An open-label, randomized, controlled clinical trial to explore the efficacy and safety of iMSC in preventing the development of acute graft-versus-host disease of degree III-IV in patients after allogeneic hematopoietic stem cell transplantation.

A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD

Evaluate the safety and efficacy of NCR102 injection in the treatment of SR-aGVHD patients who have failed second-line therapy.

Universal CNK-UT Therapy for Refractory aGVHD

This is a single arm, open-label, multi-center, pilot studies (Investigator Initiated Trial, IIT) to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of universal T-cells engineered with chimeric natural killer receptor (CNK-UT) to treat the patients with steroid-refractory/resistant or steroid-dependent aGVHD.

Tissue-resident Immune Cell Subsets in aGVHD

This is a prospective study investigating the role of tissue-resident immune cell subsets in the occurrence and progression of graft-versus-host disease following hematopoietic stem cell transplantation. Approximately 40 subjects(including 20 grade 3-4 aGVHD patients and 20 grade 1-2 aGVHD patients ).

Donor Neutrophil Subsets to Predict the Risk of aGVHD

This is a prospective study to explore the association between donor neutrophil subsets and acute graft-vs.-host disease outcomes. Approximately 260 subjects (including 130 donors and 130 corresponding recipients) will be recruited.